Better Health for All

Kazia Therapeutics' core business is focused on developing novel anti-cancer drugs. Its lead drug candidate, paxalisib, demonstrated a 3.8-month (approximately 33%) improvement in overall survival for newly diagnosed unmethylated glioblastoma patients compared to standard of care in a Phase II/III trial.

Another candidate, EVT801, showed a 46% stable disease rate in patients with advanced ovarian cancer in a Phase 1 trial, with one patient experiencing a partial response. Both paxalisib and EVT801 were reported as well-tolerated in their respective trials, with no new safety signals identified for paxalisib and the majority of EVT801 toxicities being mild to moderate and transient. Paxalisib has received multiple regulatory designations from the FDA, including Orphan Drug Designation and Fast Track Designation for glioblastoma and other indications, as well as Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumours.

Fair Money & Economic Opportunity

Kazia Therapeutics Limited is an oncology-focused biotechnology company engaged in the development of novel anti-cancer drugs. The provided articles discuss corporate financing activities such as a registered direct offering

and a reverse stock split , as well as the company's core business of cancer drug development. None of the articles indicate that Kazia Therapeutics Limited operates as a financial institution or offers lending, deposit, or other financial services to consumers. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's business model.

Kind to Animals

Kazia Therapeutics conducts animal testing as a standard part of its drug development process.

This includes a 13-week animal toxicology study for GDC-0084 in two animal species under Good Laboratory Practice (GLP) conditions, commenced in compliance with FDA guidelines. Preclinical models, such as murine (mouse) models, are also used in research for drug candidates like NDL2 and paxalisib to characterize safety profiles and for preclinical proof of concept. The company used approximately 11,500 animals for testing in 2018.

No War, No Weapons

Kazia Therapeutics is an oncology-focused drug development company and is not a defense contractor.

The company's core business does not involve arms or defense-related activities, dual-use technologies, or sales to embargoed regimes. There is no mention of peacebuilding initiatives, conflict divestment policies, defense-related board oversight, export compliance, lobbying for arms control, humanitarian procurement, human rights due diligence in conflict zones, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance contracts, ethical red lines for weapons, exposure to controversial weapons, war-related supply chain audits, conflict partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict zones. All relevant KPIs are noted as 'Not applicable' in the provided evidence, indicating no involvement in these areas.

Planet-Friendly Business

The company provides no specific quantitative data on its own environmental performance, including greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or packaging CO2 reduction.

There is no information on the existence of science-based targets, EU Taxonomy alignment, lifecycle impact assessments, or carbon offset quality for Kazia Therapeutics. While its head office is located in a carbon-neutral commercial precinct with a five-star NABERS energy-rated building, and a major partner (Evotec) is an SBTi signatory and procures green electricity, these actions are not directly attributable to Kazia's company-wide operations or specific to its own environmental metrics. No environmental compliance violations, fines, or regulatory actions are mentioned for Kazia.

Respect for Cultures & Communities

The provided articles, including annual reports and company communications, do not contain any specific, concrete data points or information related to Kazia Therapeutics Limited's respect for cultures and communities. There is no evidence regarding formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, community complaint resolution times, FPIC participation rates, community governance inclusion, cultural preservation investments, local procurement, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocations, language inclusivity, cultural incident response, or cultural sensitivity training completion.

The reports primarily focus on clinical trials, pipeline, and financial performance, with one mention of environmental sustainability efforts by a partner, but no information relevant to the specified cultural and community metrics.

Zero Waste & Sustainable Products

No specific data or information regarding KZIA.US's performance on waste management, product recyclability, packaging sustainability, or any other 'Zero Waste & Sustainable Products' KPIs is available in the provided articles.

All articles explicitly state that no relevant data for KZIA.US could be found for these metrics.